1. Home
  2. PHXM

PHXM

PHAXIAM Therapeutics S.A..

Logo PHAXIAM Therapeutics S.A..

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

0

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.

Founded: 2004 Country:
France
France
Employees: N/A City: N/A
Market Cap: 18.8M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 1.8K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.83 EPS Growth: N/A
52 Week Low/High: $2.50 - $13.00 Next Earning Date: 05-07-2024
Revenue: $6,562,637 Revenue Growth: 44.29%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: